Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex ...